Biogen
BIIB
1,039 hedge funds and large institutions have $35B invested in Biogen in 2021 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 350 increasing their positions, 399 reducing their positions, and 124 closing their positions.
0.71% less ownership
Funds ownership: 83.76% → 83.05% (-0.71%)
6% less funds holding
Funds holding: 1,104 → 1,039 (-65)
12% less repeat investments, than reductions
Existing positions increased: 350 | Existing positions reduced: 399
20% less capital invested
Capital invested by funds: $43.5B → $35B (-$8.53B)
27% less call options, than puts
Call options by funds: $1.24B | Put options by funds: $1.7B
42% less first-time investments, than exits
New positions opened: 72 | Existing positions closed: 124
44% less funds holding in top 10
Funds holding in top 10: 27 → 15 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$226M |
| 2 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
+$136M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$131M |
| 4 |
JP Morgan Chase
New York
|
+$82.1M |
| 5 |
Amundi
Paris,
France
|
+$77.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$210M |
| 2 |
D.E. Shaw & Co
New York
|
-$135M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$115M |
| 4 |
Renaissance Technologies
New York
|
-$114M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$101M |
BIIB Hedge Fund Activity: Q3 2021 in Review
1,039 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2021, worth a combined $35B — down 20% from $43.5B a quarter earlier.
Sellers outnumbered buyers: 124 funds closed out of BIIB and 72 opened new positions — a net loss of 52 holders — while 399 trimmed existing stakes and 350 added.
The largest buyer was BlackRock, adding an estimated $226M. The largest seller was Marshall Wace, cutting an estimated $210M.
- 1,039 institutional investors held Biogen (BIIB) as of Q3 2021, down from 1,104 in Q2 2021.
- Funds reported $35B of Biogen stock for Q3 2021, down 20% quarter-over-quarter.
- 72 funds opened new Biogen positions in Q3 2021 and 124 closed out, a net change of -52 holders.
- The largest Biogen buyer in Q3 2021 was BlackRock, an estimated $226M added.
- The largest Biogen seller in Q3 2021 was Marshall Wace, an estimated $210M sold.
Based on aggregated 13F filings for Q3 2021.